A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation

A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation

Abstract Poly(ADP‐ribose) polymerase (PARP) inhibitors (PARPi) are effective in cancers with defective homologous recombination DNA repair (HRR), including BRCA1/2‐related cancers. A test to identify additional HRR‐deficient tumors will help to extend their use in new indications. We evaluated the a...

Full description

Bibliographic Details
Main Authors: Marta Castroviejo‐Bermejo, Cristina Cruz, Alba Llop‐Guevara, Sara Gutiérrez‐Enríquez, Mandy Ducy, Yasir Hussein Ibrahim, Albert Gris‐Oliver, Benedetta Pellegrino, Alejandra Bruna, Marta Guzmán, Olga Rodríguez, Judit Grueso, Sandra Bonache, Alejandro Moles‐Fernández, Guillermo Villacampa, Cristina Viaplana, Patricia Gómez, Maria Vidal, Vicente Peg, Xavier Serres‐Créixams, Graham Dellaire, Jacques Simard, Paolo Nuciforo, Isabel T Rubio, Rodrigo Dienstmann, J Carl Barrett, Carlos Caldas, José Baselga, Cristina Saura, Javier Cortés, Olivier Déas, Jos Jonkers, Jean‐Yves Masson, Stefano Cairo, Jean‐Gabriel Judde, Mark J O'Connor, Orland Díez, Judith Balmaña, Violeta Serra
Format: Article
Language:English
Published: Springer Nature 2018-12-01
Series:EMBO Molecular Medicine
Subjects:
BRCA1
homologous recombination
PALB2
PARP inhibitors
RAD51
Online Access:https://doi.org/10.15252/emmm.201809172

Similar Items

Similar Items